Researchers found that popular weight-loss medications known as GLP-1 receptor agonists, like semaglutide, can significantly reduce the risk of heart attacks, strokes, and premature death. A comprehensive review of over 90,000 participants in international clinical trials revealed that these drugs not only help with weight loss and blood sugar management but also provide substantial long-term benefits for heart health.

For people looking to age well, this means that using GLP-1 medications could offer protection against serious cardiovascular issues, especially for those at higher risk, such as individuals with obesity, type 2 diabetes, or existing heart conditions. The analysis showed a 13% reduction in major cardiovascular events among those taking these medications compared to those on a placebo. Additionally, participants using GLP-1 drugs were less likely to experience non-fatal heart attacks, strokes, or hospitalizations for heart failure, suggesting a dual benefit of weight management and heart health.

The evidence comes from a systematic review of 11 major trials that monitored participants for an average of nearly three years. While the findings are promising, they are based on clinical data and are particularly relevant for high-risk populations. There were no significant increases in severe safety risks, although some gastrointestinal side effects, like nausea, were more common. This research could influence future healthcare strategies, especially as cardiovascular disease remains a leading cause of death.

If you are considering GLP-1 medications, discuss with your healthcare provider about the potential heart health benefits, especially if you have risk factors for cardiovascular disease.

Source: sciencedaily.com